scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1004654264 |
P356 | DOI | 10.1038/SJ.BMT.1705145 |
P698 | PubMed publication ID | 16113661 |
P50 | author | Koji Izutsu | Q73006741 |
P2093 | author name string | S Ogawa | |
H Hirai | |||
T Watanabe | |||
M Kurokawa | |||
S Chiba | |||
Y Kanda | |||
K Oshima | |||
T Motokura | |||
M Sakata-Yanagimoto | |||
E Shoda | |||
Y Asano-Mori | |||
P2860 | cites work | High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H | Q28215194 |
Phase II study of alemtuzumab in chronic lymphoproliferative disorders | Q33349421 | ||
Pathophysiological role of cytokines in congestive heart failure | Q34131932 | ||
Engraftment syndrome following hematopoietic stem cell transplantation | Q34298239 | ||
The CD52 antigen and development of the CAMPATH antibodies | Q34780507 | ||
Inflammatory mediators and the failing heart: past, present, and the foreseeable future | Q35011415 | ||
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome | Q35741601 | ||
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen | Q43863962 | ||
BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. | Q44582243 | ||
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning | Q44826910 | ||
Early and late elevation of plasma atrial and brain natriuretic peptides in patients after bone marrow transplantation | Q48788011 | ||
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity | Q61651657 | ||
Regimen-related toxicity in patients undergoing bone marrow transplantation | Q70215525 | ||
Treatment of T-cell prolymphocytic leukemia with human CD52 antibody | Q73494835 | ||
Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab | Q73888073 | ||
Predictors for severe cardiac complications after hematopoietic stem cell transplantation | Q79872383 | ||
In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation | Q81778094 | ||
P433 | issue | 9 | |
P921 | main subject | stem cell transplantation | Q65592366 |
P304 | page(s) | 821-824 | |
P577 | publication date | 2005-11-01 | |
P1433 | published in | Bone Marrow Transplantation | Q4941523 |
P1476 | title | Cardiac complications after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab | |
P478 | volume | 36 |
Search more.